Catalyst Event

HUTCHMED (China) Limited (13) · Other

From Akros SCHK HK-U.S. Biotech Index (ASHUBIO)

4/29/2026, 12:00:00 AM

OtherSentiment: Positive

The New Drug Application (NDA) for sovleplenib for the treatment of warm antibody autoimmune hemolytic anemia (wAIHA) was accepted and granted Priority Review and Breakthrough Therapy Designation by the China National Medical Products Administration (NMPA).

Korean Translation

중국 국가약품감독관리국(NMPA)으로부터 온난항체 자가면역성 용혈성빈혈(wAIHA) 치료제 소보레플레닙(sovleplenib)의 신약허가신청(NDA)이 접수되고 우선심사 및 혁신치료제로 지정됨.

Related Recent Events

View Full Timeline